Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16702582 | 0.98 | ALDH1A1 (0.52) | ALDH1A1IDO1MEN1KMT2AGAA | |
| SCHEMBL3068902 | 0.89 | F2 (0.43) | ALDH1A1GAAMAPTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL28092299 | 0.86 | MAPT (0.46) | ALDH1A1IDO1MEN1KMT2AGAA | |
| SCHEMBL4101986 | 0.85 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4029597 | 0.83 | ALDH1A1 (0.61) | ALDH1A1IDO1MEN1KMT2AGAA | |
| SCHEMBL173657 | 0.83 | ALDH1A1 (0.54) | ALDH1A1IDO1MEN1KMT2AGAA | |
| SCHEMBL29430229 | 0.82 | ALDH1A1 (0.52) | ALDH1A1IDO1MEN1KMT2AGAA | |
| SCHEMBL28592175 | 0.82 | PEPD (0.52) | ALDH1A1MEN1KMT2AGAALMNA | |
| Hydrochloric Acid SCHEMBL9957962 | 0.81 | ALDH1A1 (0.59) | ALDH1A1IDO1MEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL4372005 | 0.81 | ALDH1A1 (0.50) | ALDH1A1IDO1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114437685-B | Degradable dynamic polymer plugging material and preparation method and application thereof | 四川大学 | 2022-12-23 | — | — | CN | claimed |
| CN-114437685-A | Degradable dynamic polymer plugging material and preparation method and application thereof | 四川大学 | 2022-05-06 | — | — | CN | claimed |
| CN-108503813-B | Curing agent for carboxyl resin, preparation method and application composition | 黄山华惠科技有限公司 | 2020-02-18 | — | — | CN | claimed |
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2019-05-16 | — | — | US | claimed |
| CN-108503813-A | A kind of carboxy resin curing agent, preparation method and application composition | 黄山华惠科技有限公司 | 2018-09-07 | — | — | CN | claimed |
| US-20170333370-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-11-23 | — | — | US | claimed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | claimed |
| CN-114437685-B | Degradable dynamic polymer plugging material and preparation method and application thereof | 四川大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-114437685-A | Degradable dynamic polymer plugging material and preparation method and application thereof | 四川大学 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021022224-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF THEIR USE IN THE INHIBITION OF INTERACTION BETWEEN IL18 AND IL18R | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020232056-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-19 | — | — | WO | disclosed |
| US-10716771-B2 | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC CORPORATION FOUNDATION (KR) | 2020-07-21 | — | — | US | disclosed |
| US-10716771-B2 | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC CORPORATION FOUNDATION (KR) | 2020-07-21 | — | — | US | disclosed |
| US-5859218-A | MOLECULAR DISTILLING MONOGLYCOSIDE FROM MIXTURE OF ALKYL MONOGLYCOSIDE AND ALKYL POLYGLYCOSIDE; ENHANCED SURFACTANT PROPERTIES | HENKEL CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5734029-A | FOAMING CLEANING PRODUCT | HENKEL CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
| US-5449763-A | Detergents, surfactants | HENKEL CORPORATION (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0643717-A1 | PREPARATION OF ALKYLPOLYGLYCOSIDES | HENKEL CORPORATION (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0607198-A1 | PREPARATION OF IMPROVED ALKYLPOLYGLYCOSIDE SURFACTANT MIXTURES | HENKEL CORPORATION (US) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007160-A1 | PREPARATION OF ALKYLPOLYGLYCOSIDES | HENKEL CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| WO-1993007249-A1 | PREPARATION OF IMPROVED ALKYLPOLYGLYCOSIDE SURFACTANT MIXTURES | HENKEL CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10716771-B2 | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient | IL17A, TNF, IL2 | ALDH1A1 2223/4885IDO1 99/4885MEN1 3499/4885 |
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | ALDH1A1 2430/4885IDO1 4081/4885MEN1 351/4885 |
| US-20170333370-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | IL17A, TNF, IL2 | ALDH1A1 2223/4885IDO1 99/4885MEN1 3499/4885 |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | ALDH1A1 2430/4885IDO1 4081/4885MEN1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.